公开(公告)号：US20080254040A1

公开(公告)日：2008-10-16

申请号：US12140661

申请日：2008-06-17

申请人： Martin Friedrich STEFANIC ,  Frank HILBERG ,  Gerd MUNZERT ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

发明人： Martin Friedrich STEFANIC ,  Frank HILBERG ,  Gerd MUNZERT ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

IPC分类号： A61K39/395 ,  A61K31/496 ,  A61K38/19 ,  A61K31/553 ,  A61P35/00 ,  A61K31/517 ,  A61K38/43

CPC分类号： A61K31/496 ,  A61K31/404 ,  A61K31/517 ,  A61K31/553 ,  A61K31/56 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

摘要翻译： 本发明涉及用于治疗涉及骨髓瘤细胞的细胞增殖，迁移或凋亡或血管发生的疾病的药物组合。 本发明还涉及一种治疗所述疾病的方法，包括以提供添加剂和协同效应的比例共同给予有效量的特定活性化合物和/或与放射治疗共同给药，以及组合 使用这些特定化合物和/或放射治疗来制造相应的药物组合制剂。

公开(公告)号：US20140057898A1

公开(公告)日：2014-02-27

申请号：US14071166

申请日：2013-11-04

申请人： Martin Friedrich STEFANIC ,  Frank HILBERG ,  Gerd MUNZERT ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

发明人： Martin Friedrich STEFANIC ,  Frank HILBERG ,  Gerd MUNZERT ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

IPC分类号： A61K31/496 ,  A61K31/553

CPC分类号： A61K31/496 ,  A61K31/404 ,  A61K31/517 ,  A61K31/553 ,  A61K31/56 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

摘要翻译： 本发明涉及用于治疗涉及骨髓瘤细胞的细胞增殖，迁移或凋亡或血管发生的疾病的药物组合。 本发明还涉及一种治疗所述疾病的方法，包括以提供添加剂和协同效应的比例共同给予有效量的特定活性化合物和/或与放射治疗共同给药，以及组合 使用这些特定化合物和/或放射治疗来制造相应的药物组合制剂。

公开(公告)号：US20130289014A1

公开(公告)日：2013-10-31

申请号：US13930232

申请日：2013-06-28

申请人： Flavio SOLCA ,  Ulrich GUERTLER ,  Ulrike TONTSCH-GRUNT

发明人： Flavio SOLCA ,  Ulrich GUERTLER ,  Ulrike TONTSCH-GRUNT

IPC分类号： A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  A61K31/5377

CPC分类号： A61K31/496 ,  A61K31/00 ,  A61K31/404 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of a cell signalling and/or angiogenesis inhibitor in conjunction with an Aurora kinase inhibitor.

摘要翻译： 本发明涉及用于治疗肿瘤和纤维化疾病的新方法，包括联合给予细胞信号传导和/或血管发生抑制剂与极光激酶抑制剂。

公开(公告)号：US20130178487A1

公开(公告)日：2013-07-11

申请号：US13766914

申请日：2013-02-14

申请人： Flavio SOLCA ,  Andree AMELSBERG ,  Jacobus C.A. van MEEL ,  Anke BAUM ,  Gerd STEHLE

发明人： Flavio SOLCA ,  Andree AMELSBERG ,  Jacobus C.A. van MEEL ,  Anke BAUM ,  Gerd STEHLE

IPC分类号： A61K31/517

CPC分类号： A61K31/517 ,  A61K31/553 ,  A61K33/24

摘要： The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.

公开(公告)号：US20110171289A1

公开(公告)日：2011-07-14

申请号：US12912110

申请日：2010-11-09

申请人： Martin Friedrich STEFANIC ,  Frank HILBERG ,  Gerd MUNZERT ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

发明人： Martin Friedrich STEFANIC ,  Frank HILBERG ,  Gerd MUNZERT ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

IPC分类号： A61K9/127 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/395 ,  A61K31/506 ,  A61K31/675 ,  A61K33/24 ,  A61K31/7008 ,  A61K31/66 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/14 ,  A61K38/21 ,  A61K31/57 ,  A61K38/20 ,  A61K38/16 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/496 ,  A61K31/404 ,  A61K31/517 ,  A61K31/553 ,  A61K31/56 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

公开(公告)号：US20110039863A1

公开(公告)日：2011-02-17

申请号：US12912090

申请日：2010-10-26

申请人： Frank HILBERG ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

发明人： Frank HILBERG ,  Flavio SOLCA ,  Anke BAUM ,  Jacobus C.A. van MEEL

IPC分类号： A61K31/496 ,  A61P35/00

CPC分类号： A61K31/496 ,  A61K31/404 ,  A61K31/517 ,  A61K31/553 ,  A61K31/56 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

公开(公告)号：US20100010023A1

公开(公告)日：2010-01-14

申请号：US12563340

申请日：2009-09-21

申请人： Frank HIMMELSBACH ,  Elke LANGKOPF ,  Stefan BLECH ,  Birgit JUNG ,  Anke BAUM ,  Flavio SOLCA

发明人： Frank HIMMELSBACH ,  Elke LANGKOPF ,  Stefan BLECH ,  Birgit JUNG ,  Anke BAUM ,  Flavio SOLCA

IPC分类号： A61K31/517 ,  C07D239/94 ,  C07D413/02 ,  C07D405/02 ,  A61P35/00

CPC分类号： C07D405/12 ,  C07D239/94

摘要： A compound of general formula I wherein: Ra is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; Rb is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetra-hydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetra-hydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and Rc is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

摘要翻译： 通式I的化合物，其中：R a是苄基，1-苯乙基或3-氯-4-氟苯基; Rb是二甲基氨基，N-甲基-N-乙基氨基，二乙基氨基，N-甲基-N-异丙基氨基，N-甲基-N-环丙基氨基，N-甲基-N-（2-甲氧基乙基）氨基，N-乙基-N- （2-甲氧基乙基）氨基，双（2-甲氧基乙基）氨基，吗啉代，N-甲基-N-（四氢呋喃-3-基）氨基，N-甲基-N-（四氢呋喃-2-基甲基）氨基，N - 甲基-N-（四氢呋喃-3-基甲基）氨基，N-甲基-N-（四氢吡喃-4-基）氨基或N-甲基-N-（四氢吡喃-4-基甲基）氨基; Rc为环丙基甲氧基，环丁氧基，环戊氧基，四氢呋喃-3-基氧基，四氢呋喃-2-基甲氧基，四氢呋喃-3-基甲氧基，四氢吡喃-4-基氧基或四氢吡喃-4-基甲氧基，或互变异构体，立体异构体或盐 特别是其具有有价值的药理学特性的无机或有机酸或碱的生理上可接受的盐，特别是对由酪氨酸激酶介导的信号转导的抑制作用，它们在治疗疾病尤其是肿瘤疾病和肺疾病中的用途 和气道及其制备。